Serono-Ono co-co- for go/no-go on so-so onco Stimuvax
This article was originally published in Scrip
Executive Summary
Merck Serono and Ono Pharmaceutical have signed a licence agreement providing Ono with co-development and co-marketing rights to Merck's investigational therapeutic cancer immunotherapy Stimuvax in Japan. Stimuvax (BLP25 liposome vaccine), which is designed to stimulate the body's immune system to target cancer cells that express the tumour antigen MUC-1, is in Phase III for the treatment of patients suffering from non-small cell lung cancer. Merck had originally obtained the exclusive worldwide licensing rights from Oncothyreon.